339 related articles for article (PubMed ID: 27472162)
1. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.
Simón-Gracia L; Hunt H; Scodeller PD; Gaitzsch J; Braun GB; Willmore AM; Ruoslahti E; Battaglia G; Teesalu T
Mol Cancer Ther; 2016 Apr; 15(4):670-9. PubMed ID: 26880267
[TBL] [Abstract][Full Text] [Related]
3. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
[TBL] [Abstract][Full Text] [Related]
4. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
5. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
[TBL] [Abstract][Full Text] [Related]
6. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery.
Hu Q; Gu G; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Xia H; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 Jan; 34(4):1135-45. PubMed ID: 23146434
[TBL] [Abstract][Full Text] [Related]
7. Trimethyl chitosan based conjugates for oral and intravenous delivery of paclitaxel.
He R; Yin C
Acta Biomater; 2017 Apr; 53():355-366. PubMed ID: 28189812
[TBL] [Abstract][Full Text] [Related]
8. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.
Li L; Yang M; Li R; Hu J; Yu L; Qian X
Anticancer Agents Med Chem; 2021; 21(7):910-918. PubMed ID: 32698755
[TBL] [Abstract][Full Text] [Related]
9. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
[TBL] [Abstract][Full Text] [Related]
10. Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells.
Arduino I; Liu Z; Iacobazzi RM; Lopedota AA; Lopalco A; Cutrignelli A; Laquintana V; Porcelli L; Azzariti A; Franco M; Santos HA; Denora N
Int J Pharm; 2021 Dec; 610():121246. PubMed ID: 34737115
[TBL] [Abstract][Full Text] [Related]
11. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
[TBL] [Abstract][Full Text] [Related]
12. Tumor-penetrating iRGD peptide inhibits metastasis.
Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
[TBL] [Abstract][Full Text] [Related]
13. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
[TBL] [Abstract][Full Text] [Related]
14. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.
Hunt H; Simón-Gracia L; Tobi A; Kotamraju VR; Sharma S; Nigul M; Sugahara KN; Ruoslahti E; Teesalu T
J Control Release; 2017 Aug; 260():142-153. PubMed ID: 28603028
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-loaded polymeric micelles based on poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) triblock copolymers: in vitro and in vivo evaluation.
Zhang L; He Y; Ma G; Song C; Sun H
Nanomedicine; 2012 Aug; 8(6):925-34. PubMed ID: 22101107
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer.
Yin T; Wang L; Yin L; Zhou J; Huo M
Biomaterials; 2015 Aug; 61():10-25. PubMed ID: 25996409
[TBL] [Abstract][Full Text] [Related]
17. Theranostic iRGD peptide containing cisplatin prodrug: Dual-cargo tumor penetration for improved imaging and therapy.
Cho HJ; Park SJ; Lee YS; Kim S
J Control Release; 2019 Apr; 300():73-80. PubMed ID: 30831135
[TBL] [Abstract][Full Text] [Related]
18. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
19. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles.
Gao Y; Zhou Y; Zhao L; Zhang C; Li Y; Li J; Li X; Liu Y
Acta Biomater; 2015 Sep; 23():127-135. PubMed ID: 26013038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]